Browse 1,565 thyroid cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Most thyroid cancers grow slowly and have some of the best outcomes of any cancer, which is why some small ones can now be safely monitored instead of removed right away. A small share behave very differently: cancers that stop responding to radioactive iodine, inherited medullary thyroid cancer, and the rare but aggressive anaplastic type. Targeted medicines matched to specific gene changes have opened new options for these groups.
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
for
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06318897
Phase 2, Recruiting
QTX3034 in Patients With KRAS G12D Mutation
for
Solid Tumors
Location: New Haven CT, The Bronx NY, New York NY, Fairfax VA,
Sponsor: Quanta Therapeutics
Sex: All
Age: 18+
Code: NCT06227377
Phase 1, Recruiting
A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours
for
Cancer: Recurrent and/or Metastatic Solid Tumours
Location: Edmonton
Sponsor: PharmaMatrix Holdings Ltd
Sex: All
Age: 18+
Code: NCT04823897
Phase 1, Recruiting
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
for
Cancer
Location: Lexington KY
Sponsor: Rachel Miller
Sex: All
Age: 18+
Code: NCT03089554
Phase 2, Recruiting
Feasibility Study of CBCT for IGRT in Cancer Patients
for
Head and Neck Cancers, Breast Cancer, Thoracic Cancers,
Location: Columbus OH
Sponsor: Varian, a Siemens Healthineers Company
Sex: All
Age: 18+
Code: NCT06681233
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
for
Head and Neck Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT03145077
Recruiting
Norris ORIEN Total Cancer Care
for
Cancer Risk, Malignant Neoplasm
Location: Los Angeles CA
Sponsor: University of Southern California
Sex: All
Age: 18+
Code: NCT02970045
Recruiting
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
for
Primary Extra-cranial Solid Tumor,
Location: Boston MA, New York NY, Atlanta GA, Cincinnati OH,